Previous 10 | Next 10 |
2024-05-07 08:02:30 ET More on Heron Therapeutics Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain Heron Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript Heron Th...
Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates PR Newswire Net Product Sales of $34.7 million , which increased from $29.6 million for the same period in 2023. Net Loss Per Share $(0.02) , which decreased...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...
2024-05-06 10:57:47 ET More on Heron Therapeutics Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain Heron Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript Heron Th...
Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 PR Newswire SAN DIEGO , April 24, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the compa...
Heron Therapeutics, Inc. (NASDAQ: HRTX) is one of today's top gainers. The company's shares have moved 19.5% on the day to $3.1. Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its prop...
2024-04-16 16:24:08 ET Summary HRTX has received approval for its supplemental New Drug Application for Zynrelef, allowing its use in more surgical procedures. The company has partnered with Crosslink Life Sciences to promote Zynrelef, which could further drive sales growth. T...
Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City PR Newswire SAN DIEGO , April 11, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that it will host an Investor Day on...
Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference PR Newswire SAN DIEGO , March 28, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that Craig C...
2024-03-13 15:35:28 ET A California-based %Biotech company saw its shares soar on Wednesday, a day following the company’s Q4 earnings announcement. With analysts expecting a net loss of $0.16 per diluted share, %HeronTherapeutics (Nasdaq: HRTX) Q4 results came in at a net lo...
News, Short Squeeze, Breakout and More Instantly...
Heron Therapeutics Inc. Company Name:
HRTX Stock Symbol:
NASDAQ Market:
Heron Therapeutics Inc. Website:
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System PR Newswire SAN DIEGO , July 15, 2024 /PRNewswire/ -- Heron Therapeutics, Inc....
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire -The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of September 23, 2024 ...
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire SAN DIEGO , May 29, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechn...